Journal of Clinical and Aesthetic Dermatology

OCT 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link:

Contents of this Issue


Page 46 of 55

47 JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY October 2017 • Volume 10 • Number 10 C A S E R E P O R T agents that can potentially cause a fixed drug eruption. REFERENCES 1. Sierpina VS, Wollschlaeger B, Blumenthal M. Ginkgo biloba. Am Fam Physician. 2003;68(5):923–926. 2. Mahadevan S, Park Y. Multifaeted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. J Food Sci. 2008;73(1):R14–R19. 3. Sasseville D: Clinical patterns of phytodermatitis. Dermatol Clin. 2009;27:299–308. 4. Sowers WF, Weary PE, Collins GD, Cawley EP. Ginkgo-tree dermatitis. Arch Dermatol. 1965;91:452–456. 5. Tomb RR, Foussereau J, Sell Y. Mini-epidemic of contact dermatitis from ginkgo tree fruit (Ginkgo biloba L.). Contact Dermatitis. 1988;19(4):281– 283. 6. Bolus M. Dermatitis venenata due to Ginkgo berries [minor notes]. Arch Dermatol Syphilol. 1939;39:530. 7. Becker LE, Skipworth GB. Ginkgo-tree dermatitis, stomatitis, and proctitis. JAMA. 1975;231(11):1162–1163. 8. Chiu AE, Lane AT. Diffuse morbilliform eruption after consumption of Ginkgo biloba supplement [letter]. J Am Acad Dermatol. 2002;46(1):145–146. 9. Yuste M, Sanchez-Estella J, Santos JC, et al. [Stevens-Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulins]. Actas Dermosifiliogr. 2005;96(9):589–592. 10. Lepoittevin JP, Benezra C, Asakawa Y. Allergic contact dermatitis to Ginkgo biloba L.: relationship with urushiol. Arch Dermatol Res. 1989;281(4):227–230. 11. Micozzi MS, Pribitkin EA. Common herbal remedies, adverse reactions, and dermatologic effects. Skinmed. 2010;8(1):30–36. 12. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;(1):CD003119. 13. Fenzl E, Apecechea M, Schaltenbrand R, Friedel R. Long-term study concerning tolerance and efficacy of vinpocetine in elderly patients suffering from a mild to moderate organic psychosyndrome. In: Bes A, Cahn J, Cahn R, et al (eds). Senile dementias: early detection. London, Paris: John Libby Eurotext; 1986:580–585. 14. Bonoczk P, Gulyas B, Adam-Vizi V, et al. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull. 2000;53(3):245–254. 15. Erdo SL, Ning-sheng C, Wolff JR, Kiss B. Vinpocetine protects against excitotoxic cell death in primary cultures of rat cerebral cortex. Eur J Pharmacol. 1990;187(3):551–553. 16. Vinpocetine: uses, side effects, interactions and warnings. WebMD site. Available at: http:// ingredientmono-175-vinpocetine.aspx? activeingredientld=175&activeingredient Name=vinpocetine. Accessed August 10, 2013. 17. Ozkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges. 20098;6(3):181–188. 18. Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol. 2007;17(3):201–208. 19. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9(4):316–321. 20. Mizukawa Y, Shiohara T. Fixed drug eruption: a prototypic disorder mediated by effector memory T cells. Curr Allergy Asthma Rep. 2009;9(1):71–77. 21. Andrade P, Brinca A, Goncalo M. Patch testing in fixed drug eruptions—a 20-year review. Contact Dermatitis. 2011;65(4):195–201. JCAD

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - OCT 2017